Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.
OBJECTIVE
Intradetrusor botulinum toxin-A injection is a promising emerging therapy for neurogenic and idiopathic overactive bladder that is refractory to current antimuscarinic agents. We evaluated a sedation-free procedure using flexible endoscopy to perform intradetrusor botulinum toxin-A injection using a validated pain score to assess the tolerability of this technique.


METHODS
Five men and 22 women with idiopathic overactive bladder refractory to antimuscarinics were prospectively evaluated and randomized to 100 U (14) or 150 U botulinum toxin-A (13). Subjects underwent BTA injection with intravesical lidocaine using a 14Fr Olympus flexible cystoscope, which accommodates a 27 gauge flexible Olympus injection needle. Patients were evaluated with the visual analog scale to evaluate discomfort during and 15 minutes after the procedure. Procedure time was recorded.


RESULTS
In 22 female patients the mean pain score was 3.1 (range 0 to 10) during the procedure and 0.7 (range 0 to 7) 15 minutes after the procedure. In 5 male patients the mean pain score was 1.6 (range 0 to 3.5) during the procedure and 0.0 with all reporting no pain 15 minutes after the procedure. Mean procedure time was 4.5 minutes (range 4 to 6). Only 1 of the 27 patients requested sedation before any subsequent injections.


CONCLUSIONS
Sedation-free intradetrusor botulinum toxin-A injection using intravesical lidocaine and flexible endoscopy is a well tolerated and safe procedure to perform in an office setting.
Cohen
Brian L
BL
Department of Urology, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA.
Rivera
Rolando
R
Barboglio
Paholo
P
Gousse
Angelo
A
D000283:Administration, Intravesical; D000779:Anesthetics, Local / Q000008:administration & dosage; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D003558:Cystoscopy / Q000009:adverse effects* / Q000379:methods*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular / Q000009:adverse effects* / Q000379:methods*; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D010146:Pain / Q000209:etiology; D010147:Pain Measurement; D011446:Prospective Studies; D053201:Urinary Bladder, Overactive / Q000188:drug therapy
D000779:Anesthetics, Local; D009465:Neuromuscular Agents; D008012:Lidocaine; D019274:Botulinum Toxins, Type A